Jump to content

Inna Sekirov

From Wikipedia, the free encyclopedia

Inna Sekirov is a Moldovan-born, Canadian medical microbiologist and physician-scientist at the University of British Columbia.[1]

Biography

[edit]

Sekirov was born in Moldova and moved to Vancouver, British Columbia, Canada in 1995. She attended the University of British Columbia (UBC) and graduated with a BS in Microbiology and Immunology in 2003.[2] Sekirov carried out her PhD work at the Brett Finlay lab as a Michael Smith Foundation for Health Research Senior Graduate Trainee.[3][4] She then went on to complete her medical microbiology residency graduating with her PhD, MD, and FRCPC at UBC in 2011.[2]

She remained at UBC after graduation and became the Program Head for Tuberculosis (TB)/Mycobacteriology at the British Columbia Centre for Disease Control, and a Clinical Assistant Professor of Pathology and Laboratory Medicine at UBC.[2] Her research focused on the public health-related aspects of medical microbiology, clinical applications of microbial genomics and TB/mycobacteriology diagnostic methods.[1]

She has also led COVID-19 research projects on ACEII,[5] antibody responses,[6] and seroprevalence using dried blood spots.[7]

Selected works

[edit]
  • Coburn, Bryan, Inna Sekirov, and B. Brett Finlay. "Type III secretion systems and disease." Clinical microbiology reviews 20, no. 4 (2007): 535-549.
  • Sekirov, Inna, Nicola M. Tam, Maria Jogova, Marilyn L. Robertson, Yuling Li, Claudia Lupp, and B. Brett Finlay. "Antibiotic-induced perturbations of the intestinal microbiota alter host susceptibility to enteric infection." Infection and immunity 76, no. 10 (2008): 4726-4736.
  • Sekirov, Inna, Shannon L. Russell, L. Caetano M. Antunes, and B. Brett Finlay. "Gut microbiota in health and disease." Physiological reviews (2010).
  • Skowronski, Danuta M., Inna Sekirov, Suzana Sabaiduc, Macy Zou, Muhammad Morshed, David Lawrence, Kate Smolina et al. "Low SARS-CoV-2 sero-prevalence based on anonymized residual sero-survey before and after first wave measures in British Columbia, Canada, March-May 2020." MedRxiv (2020): 2020-07.

References

[edit]
  1. ^ a b "Inna Sekirov". bccdc.ca. Retrieved 2021-10-21.
  2. ^ a b c "Inna Sekirov". Pathology. Retrieved 2021-10-21.
  3. ^ Sekirov, Inna; Russell, Shannon L.; Antunes, L. Caetano M.; Finlay, B. Brett (2010). "Gut Microbiota in Health and Disease". Physiological Reviews. 90 (3): 859–904. doi:10.1152/physrev.00045.2009. ISSN 0031-9333.
  4. ^ "Inna Sekirov – Health Research BC". healthresearchbc.ca. Retrieved 2024-09-16.
  5. ^ "Prognostication of ACE II Receptor (PACEiiR) | COVID-19 Research". covid19.research.ubc.ca. Retrieved 2021-10-21.
  6. ^ "Characterizing Antibody Response to Emerging COVID-19 Virus (CARE COVID-19) | COVID-19 Research". covid19.research.ubc.ca. Retrieved 2021-10-21.
  7. ^ "Accelerating SARS-CoV-2 SEroprevalence SurveyS Through Dried Blood Spots (ASSESS-DBS) | COVID-19 Research". covid19.research.ubc.ca. Retrieved 2021-10-21.